Retatrutide Phase 3 Results Explained: The TRIUMPH Trials, Triple Agonism, and What Comes Next in 2026

In a therapeutic landscape already transformed by semaglutide and tirzepatide, retatrutide (LY3437943) has emerged as the most ambitious metabolic peptide in clinical development. Developed by Eli Lilly and Company, retatrutide is the first triple incretin receptor agonist — simultaneously targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Its Phase 2 results, published in the New England Journal of Medicine in 2023, demonstrated unprecedented weight loss of up to 24.2% at 48 weeks — surpassing every other anti-obesity agent in clinical development at that time.

Now in Phase 3 trials (the TRIUMPH program), retatrutide represents not just an incremental improvement but a potential paradigm shift in metabolic research. The addition of glucagon receptor agonism to the established GLP-1/GIP dual agonist framework introduces mechanisms — particularly hepatic fat oxidation and thermogenesis — that could fundamentally change the therapeutic ceiling for metabolic disease. This comprehensive guide examines the science, the trial data, and what comes next for this groundbreaking compound.

What Is Retatrutide? The First Triple Agonist

Retatrutide is a 39-amino acid single peptide chain that activates three distinct G protein-coupled receptors (GPCRs) involved in metabolic regulation. Unlike combination therapies that mix separate peptides, retatrutide achieves triple agonism through a single molecule — an engineering achievement that required careful optimization of the peptide sequence to balance activity across all three receptor targets while maintaining favorable pharmacokinetic properties.

The compound is designed for once-weekly subcutaneous injection, similar to semaglutide and tirzepatide. It incorporates fatty acid acylation modifications that extend its half-life by promoting albumin binding, enabling the weekly dosing interval that has become standard for this class.

Triple Agonism Explained: GLP-1, GIP, and Glucagon Receptors

The conceptual evolution from single to dual to triple agonism represents one of the most important developments in metabolic pharmacology. Each receptor brings distinct and complementary mechanisms:

The GLP-1 Receptor Arm: Appetite and Glucose Control

The GLP-1 receptor is the most well-characterized of retatrutide’s three targets, thanks to the clinical success of semaglutide (Wegovy/Ozempic) and liraglutide (Saxenda). GLP-1 receptor activation produces:

• Appetite suppression: Central GLP-1 receptor activation in the hypothalamus and brainstem (particularly the nucleus tractus solitarius and area postrema) reduces hunger and increases satiety signaling
• Delayed gastric emptying: Slowed gastric transit contributes to prolonged satiety after meals
• Glucose-dependent insulin secretion: GLP-1 potentiates insulin secretion only when blood glucose is elevated, reducing hypoglycemia risk
• Beta cell preservation: GLP-1 promotes beta cell survival and may stimulate beta cell proliferation in preclinical models
• Glucagon suppression: GLP-1 reduces inappropriate glucagon secretion from alpha cells, contributing to glucose control

Importantly, retatrutide’s GLP-1 receptor component is complemented by glucagon receptor agonism, creating a unique situation where glucagon action is simultaneously stimulated (at the liver) and modulated (at the pancreas). This is not contradictory — it reflects the different tissue-specific roles of glucagon signaling.

The GIP Receptor Arm: The Synergy Factor

Glucose-dependent insulinotropic polypeptide (GIP) was once considered a therapeutic dead end — early GIP receptor antagonists showed modest metabolic benefits, leading researchers to question whether GIP agonism or antagonism was the correct approach. The dramatic success of tirzepatide (a GLP-1/GIP dual agonist) resolved this debate in favor of agonism, demonstrating that combined GLP-1 + GIP receptor activation produced greater weight loss and glycemic control than GLP-1 agonism alone.

GIP receptor activation contributes through:

• Enhanced incretin effect: GIP and GLP-1 together produce greater insulin secretion than either alone (the “incretin synergy”)
• Central appetite regulation: GIP receptors in the hypothalamus contribute to energy balance regulation through mechanisms that are still being characterized
• Adipose tissue effects: GIP receptors on adipocytes influence lipid metabolism, though the exact consequences (lipolysis vs. lipogenesis) depend on the metabolic context
• Tolerability improvements: GIP co-activation may mitigate some GLP-1-related GI adverse effects (nausea, vomiting), potentially explaining the relatively good tolerability of dual agonists at high efficacy doses

The Glucagon Receptor Arm: The Game Changer

The glucagon receptor component is what truly distinguishes retatrutide from all predecessors. Glucagon receptor agonism was historically avoided in metabolic drug development due to glucagon’s glucose-raising effects. However, research over the past decade has revealed that glucagon’s metabolic actions extend far beyond glucose:

• Hepatic fat oxidation: Glucagon is a potent stimulator of hepatic beta-oxidation, driving the liver to burn stored fat for energy. This is particularly relevant for metabolic-associated steatotic liver disease (MASLD, formerly NAFLD), where hepatic lipid accumulation drives disease progression
• Energy expenditure: Glucagon stimulates thermogenesis through multiple mechanisms, including increased futile cycling, enhanced mitochondrial uncoupling, and activation of brown adipose tissue. This means retatrutide may increase total energy expenditure rather than relying solely on reduced energy intake
• Amino acid metabolism: Glucagon stimulates amino acid catabolism and ureagenesis, which may have implications for lean mass maintenance and nitrogen balance
• Lipid mobilization: Glucagon promotes lipolysis in adipose tissue, increasing free fatty acid availability for hepatic oxidation

The critical innovation in retatrutide’s design is that the hyperglycemic potential of glucagon receptor agonism is offset by the insulin-stimulating and glucose-lowering effects of simultaneous GLP-1 and GIP receptor activation. This creates a metabolic environment where the liver is burning fat (glucagon effect) while blood glucose remains controlled (GLP-1/GIP effects).

“The addition of glucagon receptor agonism to the incretin backbone represents the most significant mechanistic advance in obesity pharmacotherapy since GLP-1 receptor agonists. By activating hepatic lipid oxidation and thermogenesis, retatrutide addresses energy balance from both the intake and expenditure sides simultaneously.”

Phase 2 Results: 24.2% Weight Loss That Stunned the Field

Retatrutide’s Phase 2 trial results, published by Jastreboff et al. in the New England Journal of Medicine in June 2023, produced the most impressive weight loss data ever reported for a single pharmacological agent (PMID: 37351564).

Study Design

• Population: 338 adults with BMI ?30 (or ?27 with weight-related comorbidities) without diabetes
• Design: Randomized, double-blind, placebo-controlled, dose-ranging
• Duration: 48 weeks of treatment
• Doses tested: 1 mg, 4 mg (two titration schedules), 8 mg (two titration schedules), and 12 mg once weekly
• Primary endpoint: Percent change in body weight from baseline at 24 weeks

Key Results at 48 Weeks

Several aspects of these results were particularly notable:

• Dose-response relationship: Clear, monotonic dose-response with no plateau effect, suggesting even higher doses or longer treatment could produce additional weight loss
• The weight loss curve was still descending at 48 weeks — participants had not yet reached their nadir weight, suggesting the full potential of the drug was not yet realized
• 63% of the 12 mg group achieved ?20% weight loss — a threshold associated with resolution of obesity-related comorbidities including type 2 diabetes, sleep apnea, and osteoarthritis
• The results exceeded those of semaglutide 2.4 mg (~16% at 68 weeks) and tirzepatide 15 mg (~22.5% at 72 weeks) in cross-trial comparisons, achieved in a shorter time frame

The TRIUMPH Trial Program: Phase 3 Design and Scope

Eli Lilly launched the TRIUMPH (Triple Hormone Receptor Agonist Trial Utilising Metabolic Pathways in Humans) Phase 3 program in late 2023, with results expected to begin reporting in 2025–2026. The program includes four major trials:

TRIUMPH-1: Obesity Without Diabetes

• Population: Adults with BMI ?30 (or ?27 with comorbidities) without type 2 diabetes
• Estimated enrollment: ~1,500 participants
• Duration: 72 weeks of treatment
• Comparators: Placebo (double-blind)
• Primary endpoint: Percent change in body weight at 72 weeks
• Key secondary endpoints: Proportion achieving ?5%, ?10%, ?15%, ?20%, and ?25% weight loss; waist circumference; blood pressure; lipid parameters

TRIUMPH-2: Obesity With Type 2 Diabetes

• Population: Adults with BMI ?27 and type 2 diabetes
• Estimated enrollment: ~1,000 participants
• Duration: 72 weeks of treatment
• Comparators: Placebo (double-blind)
• Primary endpoints: HbA1c change and percent body weight change at 36 and 72 weeks
• Key secondary endpoints: Proportion achieving HbA1c <7%, <6.5%; fasting glucose; insulin sensitivity markers

TRIUMPH-3: Long-Term Cardiovascular Outcomes

• Population: Adults with overweight/obesity and established cardiovascular disease or high CV risk
• Estimated enrollment: ~17,500 participants (major outcomes trial)
• Duration: Event-driven (estimated 3–5 years)
• Primary endpoint: Major adverse cardiovascular events (MACE): cardiovascular death, non-fatal MI, non-fatal stroke
• Significance: If positive, would support a cardiovascular risk reduction indication similar to what semaglutide achieved in the SELECT trial

TRIUMPH-4: Weight Maintenance After Treatment

• Design: Withdrawal/re-randomization study examining weight regain after stopping treatment
• Key question: How much weight is regained after retatrutide discontinuation, and can intermittent dosing maintain weight loss?
• Significance: Weight regain after GLP-1 agonist discontinuation (reported at 60-70% for semaglutide in the STEP 4 trial) is a major clinical concern; this trial addresses whether triple agonism produces more durable metabolic changes

Retatrutide vs. Semaglutide: Head-to-Head Comparison

The cross-trial comparison is striking but must be interpreted with caution — different trial populations, endpoints, duration, and methodology make direct comparisons imprecise. Only a head-to-head randomized trial can definitively establish superiority. However, the magnitude of retatrutide’s Phase 2 results suggests that the glucagon receptor component adds meaningfully to the efficacy already established by GLP-1/GIP dual agonism.

Retatrutide vs. Tirzepatide: Triple vs. Dual Agonism

The most scientifically interesting comparison is between retatrutide and tirzepatide, both developed by Eli Lilly. Tirzepatide is already approved and demonstrates that GLP-1/GIP dual agonism is superior to GLP-1 alone. The question retatrutide must answer is: does adding glucagon receptor agonism to the GLP-1/GIP backbone produce clinically meaningful additional benefit?

The Phase 2 data suggests yes, and the most likely mechanism is the glucagon-driven increase in hepatic fat oxidation and energy expenditure. While GLP-1/GIP dual agonism primarily works through reduced energy intake (appetite suppression), glucagon receptor agonism adds energy expenditure to the equation. This dual-sided approach to energy balance may explain why retatrutide achieved greater weight loss in a shorter time frame than tirzepatide.

The Liver Fat Story: Potential MASLD/MASH Applications

One of the most exciting secondary findings from retatrutide’s Phase 2 program came from a parallel trial in participants with metabolic-associated steatotic liver disease (MASLD, formerly NAFLD). This study demonstrated extraordinary reductions in liver fat content:

• At 48 weeks, the 12 mg dose group showed a mean relative reduction in liver fat of approximately 86% as measured by MRI-PDFF (proton density fat fraction)
• Over 80% of participants achieved a normal liver fat threshold (?5% PDFF) — essentially complete resolution of steatosis
• These results dramatically exceeded those observed with semaglutide or tirzepatide in their respective liver fat substudies

The mechanistic explanation is straightforward: glucagon receptor agonism directly stimulates hepatic beta-oxidation, driving the liver to burn stored triglycerides. Combined with the reduced caloric intake from GLP-1/GIP-mediated appetite suppression, the liver is simultaneously receiving less fat (from reduced dietary intake and improved peripheral insulin sensitivity) while burning more (from glucagon-stimulated oxidation).

This has significant implications for MASH (metabolic-associated steatohepatitis) drug development, where liver fat reduction is a key therapeutic target. Eli Lilly is expected to pursue a MASH indication for retatrutide, potentially in a separate clinical program.

Cardiovascular Biomarker Effects

The Phase 2 trial reported improvements across multiple cardiovascular risk biomarkers:

• Blood pressure: Systolic and diastolic blood pressure decreased in dose-dependent fashion
• Lipid profile: Total cholesterol, LDL cholesterol, and triglycerides decreased; HDL cholesterol increased
• Inflammatory markers: C-reactive protein (CRP) decreased significantly, suggesting reduced systemic inflammation
• Waist circumference: Substantial reductions reflecting visceral fat loss, a key cardiovascular risk factor
• Fasting insulin and HOMA-IR: Improved insulin sensitivity independent of weight loss alone

Whether these biomarker improvements translate into reduced cardiovascular events will be answered by the TRIUMPH-3 outcomes trial. Given semaglutide’s positive SELECT trial results (20% MACE reduction), there is strong mechanistic rationale to expect cardiovascular benefit from retatrutide — potentially even greater benefit given the more pronounced metabolic improvements.

Safety and Adverse Event Profile

The Phase 2 safety data showed a predictable adverse event profile consistent with the incretin mechanism class:

Most Common Adverse Events (Phase 2)

• Nausea: 22–45% (dose-dependent), generally mild to moderate and decreasing over time
• Diarrhea: 16–26% (dose-dependent)
• Vomiting: 8–18% (dose-dependent)
• Constipation: 5–12%
• Decreased appetite: 5–15% (expected pharmacological effect)

GI Adverse Events and Dose Titration

The Phase 2 trial tested two titration schedules for the 4 mg and 8 mg doses — a faster and slower escalation. The slower titration consistently produced lower rates of GI adverse events, supporting the Phase 3 approach of gradual dose escalation. GI adverse events were most common during the dose titration phase and generally diminished with continued treatment.

Glucagon-Specific Safety Considerations

The inclusion of glucagon receptor agonism raised theoretical safety concerns that the Phase 2 trial was designed to monitor:

• Hyperglycemia: No clinically significant increases in blood glucose or HbA1c were observed, confirming that the GLP-1/GIP components adequately counterbalance glucagon’s hyperglycemic potential
• Heart rate: Small increases in resting heart rate (1–4 bpm) were observed, consistent with the GLP-1 agonist class effect
• Lean mass: Body composition data (measured by DEXA in a subset) showed that approximately 75% of weight loss was from fat mass, with 25% from lean mass — a ratio generally consistent with the expected proportion during significant weight loss
• Bone density: Not yet reported; will be an important safety parameter in Phase 3 given the magnitude of weight loss

Discontinuation Rates

Treatment discontinuation due to adverse events ranged from 4–10% across dose groups in Phase 2, comparable to or slightly higher than rates seen with tirzepatide and semaglutide. This suggests that the glucagon receptor component does not dramatically worsen tolerability when combined with appropriate GLP-1/GIP backbone agonism.

FDA Timeline Predictions: What to Expect in 2026-2027

Based on the current clinical development timeline and Eli Lilly’s public statements:

• Late 2025 – Early 2026: TRIUMPH-1 and TRIUMPH-2 primary endpoint readouts expected
• Mid-2026: Anticipated BLA (Biologics License Application) submission to FDA for obesity indication, assuming positive Phase 3 results
• Late 2026 – Early 2027: Potential FDA Advisory Committee meeting and approval decision
• 2027+: Commercial launch (if approved); potential expansion submissions for type 2 diabetes, MASH, and cardiovascular risk reduction indications
• 2028+: TRIUMPH-3 cardiovascular outcomes data expected

Industry analysts widely consider retatrutide’s approval highly likely based on the Phase 2 efficacy signal, with the key Phase 3 questions being confirmation of the weight loss magnitude, long-term safety, and characterization of optimal dosing.

Research Applications and Future Directions

Beyond its clinical development path, retatrutide has opened several new research avenues:

Understanding Glucagon-Incretin Interactions

Retatrutide provides a pharmacological tool to study how glucagon receptor activation interacts with incretin signaling in vivo — previously difficult to investigate because glucagon and GLP-1 are often reciprocally regulated. The compound allows researchers to study the metabolic consequences of simultaneous activation of all three receptors.

MASLD/MASH Mechanistic Studies

The dramatic liver fat reductions seen with retatrutide make it an invaluable research tool for studying hepatic lipid metabolism, the transition from steatosis to steatohepatitis, and the reversibility of liver fibrosis.

Energy Expenditure Research

The glucagon component provides an opportunity to study drug-induced increases in energy expenditure — a mechanism distinct from exercise-mimetic approaches studied with compounds like SLU-PP-332 or MOTS-c. Understanding how glucagon-driven thermogenesis compares to exercise-induced thermogenesis has implications for both pharmacology and exercise physiology research.

Combination Research

Researchers are exploring whether triple agonism can be further enhanced by combination with complementary mechanisms, such as:

• Amylin analogs: Amylin co-agonism may provide additional satiety signaling
• Muscle-sparing agents: Compounds that promote lean mass retention could address the lean mass loss that accompanies significant weight reduction
• NNMT inhibitors (5-Amino-1MQ): Metabolic reprogramming at the adipocyte level could complement receptor-mediated approaches

Frequently Asked Questions

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PMID: 37351564
2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PMID: 37385280
3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction–associated steatotic liver disease: a randomized phase 2 trial. Nat Med. 2024;30(7):2037-2048. PMID: 38898228
4. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(9):1234-1247. PMID: 36070752
5. Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36. PMID: 25485909
6. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
7. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(4):327-340. PMID: 35658024
8. Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749-757. PMID: 19597507
9. Habegger KM, Heppner KM, Geary N, et al. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010;6(12):689-697. PMID: 20957001
10. Loomba R, Hartman ML, Engel SS, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med. 2024;391(4):299-310. PMID: 38856224
11. Rubino DM, Greenway FL, Khalid U, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. PMID: 33755728
12. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131

About Proxiva Labs: We supply premium research-grade metabolic peptides including retatrutide, semaglutide, and tirzepatide for qualified researchers. All products undergo rigorous third-party purity testing. Browse our full research peptide catalog.